Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05133102 · ClinicalTrials.gov registry record
Longitudinal Oral Microbiome Sampling for BE
A clinical trial of Barrett Esophagus, sponsored by Columbia University.
- Recruiting
- Registry status
- 275
- Enrollment target
- 2
- Study locations
NCT05133102: Recruiting study of Barrett Esophagus, sponsored by Columbia University.
NCT05133102 is a study of Barrett Esophagus that is actively recruiting participants, run by Columbia University. The registered enrollment target is 275 participants, below the 3,557-participant average among 32 other Barrett Esophagus trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05133102, a study of Barrett Esophagus, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- 275 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a longitudinal cohort study to assess the impact of repeated sampling of an oral microbiome signature for Barrett's esophagus (BE). Potential participants will be identified through chart review of patients who have had an endoscopy in the past three years.
Primary Outcome
Using a classifier developed from 16S rRNA gene sequencing data, the investigators will calculate the area under the receiver operating curve (AUROC) and associated 95% confidence interval for a classifier with three repeated measures per subject.
Conditions Studied
Interventions
- OTHER Sample collection
Study Locations (2)
Michigan
- University of Michigan - Ann Arbor
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2021-03-19 |
| Est. Completion | 2026-08 |
What NCT05133102 shows while recruiting
NCT05133102 is an observational study that tracks outcomes without assigning an intervention. The registered 275 participants enrollment target is mid-sized for trials with a published cap, below the 3,557-participant average among 32 other Barrett Esophagus trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Barrett Esophagus appearing as the primary indexed condition, and to 1 intervention - of which Sample collection is the first listed.
NCT05133102 reports a single indexed study location in Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT05133102 about?
NCT05133102 is a clinical study titled "Longitudinal Oral Microbiome Sampling for BE". This is a longitudinal cohort study to assess the impact of repeated sampling of an oral microbiome signature for Barrett's esophagus (BE). Potential participants will be identified through chart review of patients who have had an endoscopy in the past three years.
What is the current status of trial NCT05133102?
This trial is currently recruiting. The enrollment target is 275 participants. The study started on 2021-03-19. Estimated completion is 2026-08.
What conditions does trial NCT05133102 study?
This clinical trial studies the following conditions: Barrett Esophagus.
What interventions are being tested in trial NCT05133102?
The interventions under investigation include: Sample collection (OTHER).
Who is sponsoring clinical trial NCT05133102?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05133102 being conducted?
This trial has 2 study locations across Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Barrett Esophagus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05133102's enrollment target sits among peer trials
275 16th of 32 higher than 16 of 32 other Barrett Esophagus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Barrett Esophagus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
RECRUITING · NA
-
Nonendoscopic Screening for Barrett's Esophagus in Veterans Without Chronic Reflux
RECRUITING · NA
-
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
RECRUITING
-
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples
RECRUITING · NA
-
Non-Endoscopic Detection of Barrett's Esophagus Using Methylation Biomarkers on EndoSign® Cell Collection Device Samples
RECRUITING
-
Obeticholic Acid for Prevention in Barrett's Esophagus
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269190 · 275 participants · NA
Wide-Field and High Resolution In Vivo Imaging in Visualizing Lesions in Patients With Oral Neoplasia Undergoing Surgery
- NCT01900132 · 275 participants · NA
Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteers
- NCT04104776 · 275 participants · Phase 1
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- NCT04765150 · 275 participants
Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI